IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
IGC Pharma announced its participation in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 from January 13-16, 2025. The company's management team will be available for both in-person and virtual meetings with registered investors and pharmaceutical companies. During these one-on-one meetings, they will present their business strategy, recent partnerships, achievements, and anticipated milestones. IGC will also host separate one-on-one meetings in San Francisco during JPM Week.
IGC Pharma ha annunciato la sua partecipazione a BIO Partnering @ JPM, programmato in concomitanza con la 43ª Conferenza Annuale sulla Salute J.P. Morgan 2025, che si svolgerà dal 13 al 16 gennaio 2025. Il team di gestione dell'azienda sarà disponibile per incontri sia di persona che virtuali con investitori registrati e aziende farmaceutiche. Durante questi incontri one-to-one, presenteranno la loro strategia aziendale, le recenti collaborazioni, i successi e i traguardi attesi. IGC ospiterà anche incontri separati one-to-one a San Francisco durante la settimana di JPM.
IGC Pharma anunció su participación en BIO Partnering @ JPM, programado junto con la 43ª Conferencia Anual de Salud J.P. Morgan 2025, del 13 al 16 de enero de 2025. El equipo de gestión de la empresa estará disponible para reuniones tanto presenciales como virtuales con inversores registrados y empresas farmacéuticas. Durante estas reuniones uno a uno, presentarán su estrategia comercial, asociaciones recientes, logros y hitos anticipados. IGC también organizará reuniones separadas uno a uno en San Francisco durante la Semana de JPM.
IGC Pharma는 BIO Partnering @ JPM에 참여한다고 발표했으며, 이는 제43회 JP모건 연례 헬스케어 컨퍼런스 2025와 함께 2025년 1월 13일부터 16일까지 예정되어 있습니다. 회사의 관리 팀은 등록된 투자자 및 제약 회사와의 대면 및 가상 회의에 모두 참석할 예정입니다. 이러한 일대일 회의에서 그들은 비즈니스 전략, 최근 파트너십, 성과 및 예상되는 이정표를 소개할 것입니다. IGC는 JPM 주간 동안 샌프란시스코에서 별도의 일대일 회의도 개최할 것입니다.
IGC Pharma a annoncé sa participation à BIO Partnering @ JPM, prévu en parallèle de la 43ème Conférence Annuelle sur la Santé J.P. Morgan 2025 du 13 au 16 janvier 2025. L'équipe de direction de l'entreprise sera disponible pour des réunions en personne et virtuelles avec des investisseurs et des entreprises pharmaceutiques enregistrées. Lors de ces réunions individuelles, ils présenteront leur stratégie commerciale, leurs partenariats récents, leurs réalisations et les étapes prévues. IGC organisera également des réunions individuelles séparées à San Francisco pendant la semaine de JPM.
IGC Pharma kündigte seine Teilnahme an BIO Partnering @ JPM an, das zeitgleich mit der 43. Jahrestagung zur Gesundheitskonferenz von J.P. Morgan 2025 vom 13. bis 16. Januar 2025 geplant ist. Das Managementteam des Unternehmens wird sowohl für persönliche als auch für virtuelle Treffen mit registrierten Investoren und Pharmaunternehmen zur Verfügung stehen. Während dieser persönlichen Meetings werden sie ihre Geschäftsstrategie, jüngste Partnerschaften, Erfolge und bevorstehende Meilensteine präsentieren. IGC wird auch separate persönliche Meetings in San Francisco während der JPM-Woche abhalten.
- None.
- None.
POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. Management will be available for in-person and virtual meetings.
Details of the events are as follows:
Event: BIO Partnering @ JPM
Date: January 13 - 16, 2025
Registration: https://www.bio.org/events/bio-partnering-jpm/registration
The IGC management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the Company's business strategy, recent partnerships and achievements, and anticipated milestones.
In addition, IGC Pharma will concurrently host one-on-one meetings in San Francisco during JPM Week. If you would like to schedule a meeting, please contact igc@imsinvestorrelations.com.
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
Forward-looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on accesswire.com
FAQ
When is IGC Pharma participating in BIO Partnering @ JPM 2025?
What will IGC Pharma discuss during the BIO Partnering @ JPM meetings?
How can investors schedule meetings with IGC Pharma during JPM Week 2025?
What types of meetings is IGC Pharma offering during the BIO Partnering event?
